Literature DB >> 35099633

Deeper sections reveal residual tumor cells in rectal cancer specimens diagnosed with pathological complete response following neoadjuvant treatment.

Lasse Slumstrup1,2, Susanne Eiholm3, Astrid Louise Bjørn Bennedsen4, Dea Natalie Munch Jepsen3,4, Ismail Gögenur4,5, Anne-Marie Kanstrup Fiehn3,4,5.   

Abstract

Guidelines and requirements for diagnosing pathological complete response (pCR) in rectal adenocarcinoma following neoadjuvant treatment vary, and there is currently no consensus on the appropriate number of sections to examine per formalin-fixed, paraffin-embedded (FFPE) tissue block. The consequences of systematic use of deeper sections on the diagnostic accuracy and prognosis for patients classified as ypT0 rectal cancer were investigated. In this retrospective study, 23 out of 155 patients who underwent neoadjuvant therapy and surgical resection between 2015 and 2020 were diagnosed with ypT0 rectal cancer. Three additional deeper sections were cut from each FFPE block from the primary tumor site and reviewed for presence of residual tumor cells. Additional sections revealed residual viable tumor cells in seven patients (30.4%), reducing the rate of pCR in the cohort from 14.8 to 10.3%. Of the seven patients, three patients later had local recurrence or distant metastasis during the follow-up period, compared with one patient with no residual tumor cells in deeper sections (p = 0.07). A nonsignificant reduction in disease-free survival (p = 0.08) was observed in the patients with residual tumor. Systematic use of deeper sections in evaluation of tumor regression in rectal cancer reveals the presence of residual tumor cells in a subset of patients originally diagnosed with pCR based on a single section per FFPE block. Although the results are not statistically significant, it cannot be excluded that accurately distinguishing complete from near-complete response may be clinically relevant for prognostic prediction.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Neoadjuvant treatment; Pathological complete response; Rectal cancer; Tumor regression

Mesh:

Year:  2022        PMID: 35099633     DOI: 10.1007/s00428-022-03287-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

3.  Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.

Authors:  Emmanouil Fokas; Torsten Liersch; Rainer Fietkau; Werner Hohenberger; Tim Beissbarth; Clemens Hess; Heinz Becker; Michael Ghadimi; Karl Mrak; Susanne Merkel; Hans-Rudolf Raab; Rolf Sauer; Christian Wittekind; Claus Rödel
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

4.  Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  R Ryan; D Gibbons; J M P Hyland; D Treanor; A White; H E Mulcahy; D P O'Donoghue; M Moriarty; D Fennelly; K Sheahan
Journal:  Histopathology       Date:  2005-08       Impact factor: 5.087

5.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; L Wyrwicz; E Tiret; G Brown; C Rödel; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

7.  Prognosis of rectal carcinoma after multimodal treatment: ypTNM classification and tumor regression grading are essential.

Authors:  Paul Hermanek; Susanne Merkel; Werner Hohenberger
Journal:  Anticancer Res       Date:  2013-02       Impact factor: 2.480

8.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Authors:  Lorenzo F Fanchi; Krijn K Dijkstra; José G Van den Berg; Emile E Voest; John B Haanen; Myriam Chalabi; Arend G Aalbers; Karolina Sikorska; Marta Lopez-Yurda; Cecile Grootscholten; Geerard L Beets; Petur Snaebjornsson; Monique Maas; Marjolijn Mertz; Vivien Veninga; Gergana Bounova; Annegien Broeks; Regina G Beets-Tan; Thomas R de Wijkerslooth; Anja U van Lent; Hendrik A Marsman; Elvira Nuijten; Niels F Kok; Maria Kuiper; Wieke H Verbeek; Marleen Kok; Monique E Van Leerdam; Ton N Schumacher
Journal:  Nat Med       Date:  2020-04-06       Impact factor: 53.440

9.  Comparison of short-course with long-course preoperative neoadjuvant therapy for rectal cancer: A meta-analysis.

Authors:  Ke Chen; Guoming Xie; Qi Zhang; Yanping Shen; Taoqi Zhou
Journal:  J Cancer Res Ther       Date:  2018       Impact factor: 1.805

10.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.